Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF
February 27, 2006
- AstraZeneca Starts IPAS Study on Iressa to Verify Efficacy in Orientals
February 27, 2006
- Toho to Focus on Quality of Services, Not Share: President Hamada
February 27, 2006
- Takeda Licenses Hematide from Affymax
February 27, 2006
- Replidyne, Forest to Comarket Faropenem Medoximil: Daiichi Asubio
February 27, 2006
- Kyorin Licenses KRP-203 to Novartis
February 27, 2006
- SURVEY 4 articles
February 27, 2006
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 27, 2006
- Roche Diagnostics Launches JMCoE Program Aiming at Personalized Medicine
February 27, 2006
- Drugs' Contribution to Medical Expenditure Optimization Is 0.7%: Mr Futagawa
February 27, 2006
- New Products to Offset Impact of NHI Price Cut: DSP
February 27, 2006
- New Prescription Form, Dispensing Fees Approved
February 27, 2006
- Initial Consultation Fee to Be Unified for Hospitals and Clinics
February 27, 2006
- REGULATORY NEWS IN BRIEF
February 27, 2006
- Olympus: Medical, Life Science Businesses Show Growth in 1st 3 Qtrs
February 27, 2006
- US FDA Accepts NDA for Garenoxacin: Toyama Chemical
February 27, 2006
- NEW PRODUCTS
February 27, 2006
- Continuing Reform Essential to Stabilize Social Security Systems: Health Minister Kawasaki
February 27, 2006
- SELF-MEDICATION NEWS IN BRIEF
February 27, 2006
- Varied Reactions Shown to New Medical Fees
February 27, 2006
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…